Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis

Leukemia and Lymphoma

Volumn 37, Issue 3-4, 2000, Pages 333-339

  Vener, Claudia ^a   Guffanti, Andrea ^b   Pomati, Mauro ^a   Colombi, Mariangela ^a   Aliettt, Alessandra ^a   Targia, Maria Luisa La ^a   Bamonti Catena, Fabrizia ^a   Baldini, Luca ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c Centro G Marcora   (Italy)

Author keywords

Advanced disease; Hodgkin's disease; Serum cytokines; Worse prognosis

Indexed keywords

CD30 ANTIGEN; COPPER; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER STAGING; CLINICAL ARTICLE; CYTOKINE RELEASE; FEMALE; HODGKIN DISEASE; HUMAN; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0034107973     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009089433     Document Type: Article

References (19)

1. Gruss H-J., Pinto A., Duysler J., Poppema S., Herrmann F. (1997) Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today, 18 (4), 156-163.
2. Nadali G., Tavecchia L., Zanolin E., Bonfante V., Viviani S., Camerini E., Musto P., Di Renzo N., Carotenuto M., Chilosi M., Krampera M., Pizzolo G. (1998) Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood, 91 (8), 3011-3016.
3. Hasenclever D., Diehl V. (1998) A prognostic score for advanced Hodgkin's disease. N Engl J Med, 19, 1506-1514.
4. Stein H., Hummel M., Dürkop H., Foss H-D., Herbst H. (1998) Biology of Hodgkin's disease. In The Lymphomas, edited by G.P. Canellos, T.A. Lister, J.L. Sklar, pp. 287-304. Philadelphia: W.B. Saunders Company.
5. + tumors. J Clin Oncol, 15 (11), 3355-3362.
6. Younes A., Zhao S., Zhang X, Snell V., Clodi K., Kliche K.O., Thomas E., Cabanillas F., Andreeff M. (1997) CD30-ligand and CD40-ligand expression in lymph nodes involved with Hodgkin's Disease. Ann Oncol, 8 (suppl.2), S97-S100.
7. Henderson S., Rowe M., Gregory C., Croom-Carter D., Wang F., Longnecker R., Kieff E., Rickinson A. (1991) Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell, 65, 1107-1115.
8. Diehl V., Bohlen H., Wolf J. (1994) CD30: cytokines-receptor, differentiation marker or a target molecule for specific immune response? Ann Oncol, 5, 300.
9. Gruss H.J., Ulrich D., Dower S.K., Herrmann F., Brach M.A. (1996) Activation of Hodgkin cells via the CD30-R induces autocrine secretion of interleukin-6 engaging the NF-kB transcription factor. Blood, 87 (6), 2443-2449.
10. Falini B., Pileri S., Pizzolo G., Dürkop H., Flenghi L., Stirpe F., Martelli M.F., Stein H. (1995) CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor-receptor supertarnily as a tool for diagnosis and immunotherapy. Blood, 85 (1), 1-14.
11. Herbst H., Samol J., Foss H-D., Raff T., Niedobitek G. (1997) Modulation of interleukin-6 expression in Hodgkin and Reed-Sternberg cells by Epstein-Barr virus. J Pathol, 182, 299-306.
12. Salles G., Bienvenu J., Bastion Y., Barbier Y., Doche C., Warzocha K., Gutowski M-C., Rieux C., Coiffier B. (1996) Elevated circulating levels of TNFa and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. Br J Haematol, 93, 352-9.
13. Brown R.E., Shah N.R., Lobel J.S., George B.A., Gaylord H., Simonich W.L. (1997) Interleukin-6-Associated laboratory parameters and immunohistochemistry in symptomatic stage A and B nodular sclerosing Hodgkin's disease in children. Ann Clin Lab Science, 27 (1), 26-33.
14. Seymour J.F., Talpaz M., Hagemeister F.B., Cabanillas F., Kurzrock R. (1997) Clinical correlates of elevated serum levels of inlerleukin-6 in patients with untreated Hodgkin's disease. Excerpta Medica-Am J Med, 102, 21-28.
15. Kurzrock R., Redman J., Cabanillas F., Jones D., Rothberg J., Talpaz M. (1993) Serum interleukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res, 53, 2118-2124.
16. Durkop H., Foss H-D., Demel G., Klotzbach H., Hahn C., Stein H. (1999) Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr virus-transformed lymphoid cells. Blood, 93 (2), 617-623.
17. Herbst H., Foss H-D., Samol J., Araujo I., Klotzbach H., Krause H., Agathanggelou A., Niedobitek G., Stein H. (1996) Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin disease. Blood, 87 (7), 2918-2929.
18. Sarris A.H., Kliche K.O., Pethambaram P., Preti A., Tucker S., Jackow C., Messina O., Pugh W., Hagemeister F.B., McLaughlin P., Rodriguez M.A., Romaguera J., Fritsche H., Witzig T., Duvic M., Andreeff M., Cabanillas F. (1999) Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol, 10 (4), 433-440.
19. Brice P. (1998) Prognostic factors in advanced Hodgkin's disease-Can they guide therapeutic decisions? N Engl J Med. 339 (21), 1547-1549.